
Plasma Proteins Reveal Molecular Signatures of Aging and Frailty
Plasma Proteins Reveal Molecular Signatures of Aging and Frailty
Plasma Proteins Reveal Molecular Signatures of Aging and Frailty
Evan King
VP of Life Sciences Research | Beach Bum at heart
“Ask me how to get started”
Sheri Wilcox
Scientific Liaison | Protein Queen
“Ask me technical questions”
Proteins are the internet of the human body. Now we have a search engine. Written by Dr. Stephen Williams, Chief Medical Officer of SomaLogic When
In a recent paper, a team of researchers describe overcoming an antibody-based roadblock on the way to a deeper biological understanding of SLE.
Three years ago, my 36-year-old niece, Sonya, passed away suddenly after complaining of a headache. What killed her was abnormal heart rhythm from undiagnosed nonalcoholic steatohepatitis, or fatty liver disease.
Because the SomaScan Assay does not rely on polyclonal antibodies, which are variable, SomaScan
data achieves coefficients of variation much lower than industry standards. Additionally, it is the only platform
that can be seamlessly used for the entire biomarker research pipeline from discovery to development consistently over time.
While most protein assays rely on a variation of the ELISA sandwich approach, the SomaScan Assay relies on kinetics: non-specific interactions dissociate faster. Tests have confirmed minimal cross-reactivity with closely related proteins.
A tiered dilution approach is used to measure proteins of very high abundance and very low abundance separately, such that a total range of 10 logs can be measured from just 55 μl of plasma or serum.
The largest commercial proteomic assay on the market,
providing over 7,000 protein measurements.
Breakdown of proteins on the SomaScan® Assay for which biological pathways are
known (chart generated via the PANTHER classification system http://pantherdb.org/)
The tiered approach used for SomaScan measurements enables the
detection of very rare proteins consistently without sample pre-treatment.